April #111 : Saving Lives-or Face? - by Jennifer Block

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

Absolutely Andy

Work With Me!

Bushed To The Limit

Don't Cry for Me, Preventionista

Legal Eye

Milestones

The Rubber Report

Tiny Toons

Saving Lives-or Face?

On The March

Booked & Noted

Vax Is Back

One a Day: You've Come A Long Way

Diabetes and HIV

Lentil Health Day

April Showers

Office Visit

Not A Gym Bunny?

Generics Hit Home

Why...

Founder's Letter

Mailbox

Cabin Fever

Woman To Woman

Holy Makeover!



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

April 2005

Saving Lives-or Face?

by Jennifer Block

Did Feds fudge data on an African AIDS study?

In December, a U.S.-backed Ugandan drug trial sparked scandalous headines: The Associated Press revealed that the National Institutes of Health (NIH) dismissed safety issues related to a study of single-dose nevirapine (Viramune)—the centerpiece of Bush’s 2002 African AIDS campaign—in preventing mother-to-child transmission (MTCT). NIH AIDS division head Edmund Tramont, MD, acknowledged having heavily “edited” a report to the FDA, over his staff’s objections. Months later, the reason remains unknown.

Tramont, an AIDS doc for 20 years, defended his actions as ethical, even as critics called for his head. The study’s science was “first-rate,” he said: In the five-year study’s first phase, nevirapine cut MTCT by half. Still, the NIH suspended the study in 2002 due to poor record keeping. Fifteen months later, Tramont made his revisions—the NIH acknowledges he has the authority to do so—and ordered the test clinic reopened, just in time for a Bush photo-op. Dismissing the timing as coincidental, Tramont presents himself as cutting through red tape to save lives.

But when the AP story broke, some activists began pushing for a nevirapine moratorium, others for Tramont to resign. The Rev. Jesse Jackson of the Rainbow/PUSH coalition told the media: “Research standards and drug quality that are unacceptable in the U.S. must never be pushed onto Africa.” Meanwhile, the South African government accused the NIH of treating Africans like “guinea pigs.”

While not the first choice for MTCT—even one dose can cause resistance in Mom—at $4, it’s affordable. “In a perfect world, every HIV positive mother would have combination therapy,” says Tramont. “You do what you can afford.” Many African AIDS activists agreed, arguing that nevirapine is better than nothing. At press time, the National Academy of Sciences is reviewing the study.  




[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Should the U.S. gay blood ban end?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.